Enchondromas of the Hand: Curettage With Autogenous Bone<i>vs.</i>Bioactive Glass S53P4 for Void Augmentation

Lindfors, Nina; Kukkonen, Elias; Stenroos, Antti; Nordback, Panu H.; Anttila, Turkka; Aspinen, Samuli

doi:10.21873/invivo.12826

Cited by 3 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indications of surgical treatment are pathological fractures and (19,20). The placement of bone graft or bioactive glass has been recently investigated, but no significant difference existed in the published studies (21). A study demonstrates that bone graft is essential only in cases where the cortex is thin or the lesion is near the articular surface (22).…”

Section: Discussionmentioning

confidence: 99%

Thumb Distal Phalanx Giant Enchondroma. A Case Presentation and Literature Review

AMPADIOTAKI,

VLACHOS,

PAPAGRIGORAKIS

et al. 2024

Maedica

View full text Add to dashboard Cite

Background: Enchordoma of the distal phalange of the thumb is extremely rare. Case presentation: We report a case of 31-year-old man who presented with a pathological fracture of the left thumb. Imaging evaluation revealed a lytic lesion and surgical curettage with bone graft was performed after fracture healing. Histological examination confirmed the diagnosis of enchordoma. The postoperative period was uncomplicated without signs of recurrence.Conclusion: Lytic lesions in the thumb are uncommon occurrences and necessitate a comprehensive examination to determine their potential causes. Given the significant functional role of the thumb compared to other fingers, it is crucial to undergo radiological assessment and further investigation of these lytic lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Thumb Distal Phalanx Giant Enchondroma. A Case Presentation and Literature Review

AMPADIOTAKI,

VLACHOS,

PAPAGRIGORAKIS

et al. 2024

Maedica

View full text Add to dashboard Cite

show abstract

“…Previous studies had suggested the risk of recurrence to be low after intralesional excision of benign bone tumors and filling with bioactive glass 4 , 15 , 19 . However, those studies investigated recurrences using radiographs.…”

Section: Discussionmentioning

confidence: 99%

“…Benign bone lesions may weaken the structure of bone, resulting in pain and a risk of pathologic fracture 1 . The 2 most typical bone lesions during childhood are simple bone cysts (SBCs) and aneurysmal bone cysts (ABCs) 2-4 . These lesions tend to expand and thin the cortices of the growing bone 1,4,5 .…”

mentioning

confidence: 99%

“…The 2 most typical bone lesions during childhood are simple bone cysts (SBCs) and aneurysmal bone cysts (ABCs) 2 - 4 . These lesions tend to expand and thin the cortices of the growing bone 1 , 4 , 5 . Minimally invasive treatment using corticosteroid or polidocanol injections seldom results in healing of SBCs 6 , is associated with a high risk of recurrence in SBCs, and does not restore normal bone structure when used for SBCs and ABCs 6 , 7 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Allograft Versus Bioactive Glass (BG-S53P4) in Pediatric Benign Bone Lesions

Syvänen

Serlo

Jalkanen

et al. 2023

Journal of Bone and Joint Surgery

View full text Add to dashboard Cite

Background:Benign bone cysts in children have a high risk of recurrence after bone grafting. The optimal treatment and filling material for these lesions are currently unknown.Methods:We compared cyst recurrence after intralesional curettage and filling with allograft versus bioactive glass (BG-S53P4; Bonalive) in a randomized clinical trial. The volume of recurrent cyst at 2-year follow-up was the primary outcome.Results:Of 64 eligible children, 51 (mean age, 11.1 years) were randomized to undergo filling of the cyst using morselized allograft (26) or bioactive glass (25). Twelve (46%) of the children in the allograft group and 10 (40%) in the bioactive glass group developed a recurrence (odds ratio [OR] for bioactive glass = 0.79, 95% confidence interval [CI] = 0.25 to 2.56, p = 0.77). The size of the recurrent cyst did not differ between the allograft group (mean, 3.3 mL; range, 0 to 13.2 mL) and the bioactive glass group (mean, 2.2 mL; range, 0 to 16.6 mL, p = 0.43). After adjusting for the type of lesion (aneurysmal bone cyst versus other), bioactive glass also did not prevent larger (>1 mL) recurrent cysts (adjusted OR = 0.42, 95% CI = 0.13 to 1.40, p = 0.16). The Musculoskeletal Tumor Society score improved significantly (p ≤ 0.013) from preoperatively to the 2-year follow-up in both groups (to 28.7 for bioactive glass and 29.1 for bone graft). Four (15%) of the children in the allograft group and 6 (24%) in the bioactive glass group required a reoperation during the follow-up (OR for bioactive glass = 1.74, 95% CI = 0.43 to 7.09, p = 0.50).Conclusions:Filling with bioactive glass and with allograft in the treatment of benign bone lesions provided comparable results in terms of recurrence and complications.Level of Evidence:Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

show abstract

“…There is no need for an adjuvant method. Filling the cavity with autologous bone graft is the most used method, but the use of heterologous grafts, synthetic substitutes, or even no filling 26 is reported. The expected recurrence rate is low (2–15%) 25 .…”

Section: Benign Bone Tumorsmentioning

confidence: 99%

Hand tumors

Neder Filho,

Costa,

Barros

et al. 2024

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Enchondromas of the Hand: Curettage With Autogenous Bonevs.Bioactive Glass S53P4 for Void Augmentation

Cited by 3 publications

References 26 publications

Thumb Distal Phalanx Giant Enchondroma. A Case Presentation and Literature Review

Thumb Distal Phalanx Giant Enchondroma. A Case Presentation and Literature Review

Allograft Versus Bioactive Glass (BG-S53P4) in Pediatric Benign Bone Lesions

Hand tumors

Contact Info

Product

Resources

About